Skip to main content
Log in

Hemodynamic responses to different levels of alpha-adrenergic interruption in congestive heart failure

  • Clinical Studies (Alpha-Adrenergic Blockade)
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

The effects of prazosin, clonidine, and indoramin on central and regional hemodynamic parameters and left ventricular performance were analyzed in a congestive heart failure population to compare the pharmacodynamic responses to different levels of alpha-adrenergic interruption in this condition. The sympathetic nervous system is blocked at the peripheral alpha1-receptor by prazosin, at central nervous system alpha-receptor sites (via alpha-adrenoceptor agonism) by clonidine, and at peripheral and central sites by indoramin. Prazosin and indoramin produced reductions in total systemic and pulmonary vascular resistances, mean systemic and pulmonary artery pressures, and pulmonary capillary wedge pressure with little change in heart rate. Both agents selectively increased hepatic blood flow. Clonidine also decreased pulmonary artery pressure and vascular resistance, but evoked negative inotropic and chronotropic activity and did not alter regional blood flow. In contrast to prazosin, indoramin and clonidine did not augment cardiac output or stroke volume. In the setting of congestive heart failure, the central and regional hemodynamic effects and the responses in left ventricular performance vary considerably depending on the site of alpha-adrenergic interruption.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Leier CV. Pharmacology and therapeutics of congestive heart failure.Rev Clin Basic Pharmacol 1985; 5:175–209.

    Google Scholar 

  2. Magorien RD, Triffon DW, Desch CE, et al. Prazosin and hydralazine in congestive heart failure: Regional hemodynamic effects in relation to dose.Ann Intern Med 1981; 95:5–13.

    Google Scholar 

  3. Hermiller JB, Magorien RD, Leithe ME, et al. Clonidine in congestive heart failure: A vasodilator with negative inotropic effects.Am J Cardiol 1983;51:791–795.

    Google Scholar 

  4. Leier CV, Huss P, Parrish D, et al. Preliminary observations of chronic indoramin therapy in congestive heart failure.J Cardiovasc Pharmacol 1986; 8:S112-S116.

    Google Scholar 

  5. Magorien RD, Hermiller JB, Unverferth DV, et al. Regional hemodynamic effects of clonidine in congestive heart failure.J Cardiovasc Pharmacol 1985; 7:91–96.

    Google Scholar 

  6. Leier CV, Binkley PF, Unverferth DV. Alpha1-adrenergic blockade redistributes cardiac output to the hepatic-splanchnic region in congestive heart failure: Regional hemodynamic studies with indoramin.Heart Failure 1986; Oct/Nov:231–235.

  7. Leier CV, Magorien RD, Boudoulas H, et al. The effect of vasodilator therapy on systolic and diastolic time intervals in congestive heart failure.Chest 1982; 81:723–729.

    Google Scholar 

  8. Graham RM, Pettinger WA. Prazosin.N Engl J Med 1979; 300:232–236.

    Google Scholar 

  9. Rosendorff C. Alpha-adrenoreceptors in hypertension.J Cardiovasc Pharmacol 1986; 8(2):S3-S7.

    Google Scholar 

  10. Leier CV, Desch CE, Magorien RD, et al. Positive inotropic effects of hydralazine in human subjects: Comparison with prazosin in the setting of congestive heart failure.Am J Cardiol 1980; 46:1039–1044.

    Google Scholar 

  11. Awan NA, Miller RR, Miller M, et al. Clinical pharmacology and therapeutic application of prazosin in acute and chronic refractory congestive heart failure.Am J Med 1978; 65:146–160.

    Google Scholar 

  12. Desch CE, Magorien RD, Triffon DW, et al. Development of pharmacologic tolerance to prazosin in congestive heart failure.Am J Cardiol 1979; 44:1178–1183.

    Google Scholar 

  13. Lowenstein J. Clonidine.Ann Intern Med 1980; 92:74–77.

    Google Scholar 

  14. Hermiller JB, Magorien RD, Leithe ME, et al. Clonidine in congestive heart failure: A vasodilator with negative inotropic effects.Am J Cardiol 1983; 51:791–795.

    Google Scholar 

  15. Sharma JN, Sandrew BB, Wang SC. CNS site of clonidine induced hypotension: A microiontophoretic study of bulbar cardiovascular neurons.Brain Res 1978; 151:127–133.

    Google Scholar 

  16. Shanks RG. The clinical pharmacology of indoramin.J Cardiovasc Pharmacol 1986; 8:S8-S15.

    Google Scholar 

  17. Baum T, Shropshire AT. Central and peripheral contribution to the antihypertensive action of indoramin.Eur J Pharmacol 1975; 32:30–38.

    Google Scholar 

  18. Weissler AM, Harris WS, Schoenfeld CD. Systolic time intervals in heart failure in man.Circulation 1968; 37:149–159.

    Google Scholar 

  19. Lewis RP, Rittgers MS, Forester WF, et al. A critical review of the systolic time intervals.Circulation 1977; 56:146–157.

    Google Scholar 

  20. Leithe ME, Magorien RD, Hermiller JB, et al. Relationship between central hemodynamics and regional blood flow in normal subjects and in patients with congestive heart failure.Circulation 1984; 69:57–64.

    Google Scholar 

  21. Zelis R, Flaim S. Alterations in vasomotor tone in congestive heart failure.Prog Cardiovasc Dis 1982; 24:437–459.

    Google Scholar 

  22. Packer M, LeJemtel TH. Physiologic and pharmacologic determinants of vasodilator response: A conceptual framework for rational drug therapy for chronic heart failure.Prog Cardiovasc Dis 1982; 24:275–292.

    Google Scholar 

  23. Cotsamire DL, Unverferth DV, Leier CV. The relationship between drug-induced changes in central and regional hemodynamics in congestive heart failure.Can J Cardiol 1986; 2:272–277.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Good, A.P., Unverferth, D.V. & Leier, C.V. Hemodynamic responses to different levels of alpha-adrenergic interruption in congestive heart failure. Cardiovasc Drug Ther 1, 529–534 (1988). https://doi.org/10.1007/BF02125736

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02125736

Key words

Navigation